proglumide has been researched along with Liver Neoplasms in 10 studies
Proglumide: A drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers.
proglumide : A racemate composed of equal amounts of (R)- and (S)-proglumide. A non-selective CCK antagonist that was used primarily for treatment of stomach ulcers, but has been replaced by newer drugs.
N(2)-benzoyl-N,N-dipropyl-alpha-glutamine : A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-benzoylglutamic acid with dippropylamine.
Liver Neoplasms: Tumors or cancer of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty-one patients with advanced colorectal cancer were entered into a randomized controlled trial of treatment with proglumide--a gastrin receptor antagonist." | 9.06 | A pilot randomized control trial of proglumide (a gastrin receptor antagonist) in advanced colorectal cancer. ( Ballantyne, KC; Charnley, RM; Jones, J; Morris, DL, 1990) |
| "When proglumide was given in combination with the PD-1Ab, there was a further significant increase in intratumoral CD8+ T cells, improved survival, and alterations in genes regulating tumoral fibrosis and epithelial-to-mesenchymal transition." | 5.91 | Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. ( Cao, H; Chen, W; Duka, T; Gay, MD; Golnazar, S; He, AR; Kallakury, B; Shivapurkar, N; Smith, JP; Vasudevan, S, 2023) |
| "Forty-one patients with advanced colorectal cancer were entered into a randomized controlled trial of treatment with proglumide--a gastrin receptor antagonist." | 5.06 | A pilot randomized control trial of proglumide (a gastrin receptor antagonist) in advanced colorectal cancer. ( Ballantyne, KC; Charnley, RM; Jones, J; Morris, DL, 1990) |
| "When proglumide was given in combination with the PD-1Ab, there was a further significant increase in intratumoral CD8+ T cells, improved survival, and alterations in genes regulating tumoral fibrosis and epithelial-to-mesenchymal transition." | 1.91 | Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma. ( Cao, H; Chen, W; Duka, T; Gay, MD; Golnazar, S; He, AR; Kallakury, B; Shivapurkar, N; Smith, JP; Vasudevan, S, 2023) |
| "Eleven colorectal cancer patients underwent hepatic resection for liver metastasis." | 1.30 | [Adjuvant intra-arterial chemotherapy with gastrin receptor antagonist after hepatic resection in colorectal cancer metastasis]. ( Furukawa, H; Hiratsuka, M; Imaoka, S; Ishikawa, O; Kabuto, T; Kameyama, M; Murata, K; Nakano, H; Ohigashi, H; Sasaki, Y; Tsugawa, T; Yasuda, T, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (70.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shivapurkar, N | 3 |
| Gay, MD | 3 |
| He, AR | 1 |
| Chen, W | 1 |
| Golnazar, S | 1 |
| Cao, H | 3 |
| Duka, T | 1 |
| Kallakury, B | 2 |
| Vasudevan, S | 1 |
| Smith, JP | 3 |
| Safronenka, A | 2 |
| Liu, FH | 1 |
| Malchiodi, ZX | 1 |
| Tucker, RD | 2 |
| Kroemer, A | 1 |
| Ciofoaia, V | 1 |
| Nadella, S | 1 |
| Huber, M | 1 |
| Kruger, AJ | 1 |
| Kroemer, AHK | 1 |
| Anand, A | 2 |
| Kameyama, M | 2 |
| Nakamori, S | 1 |
| Imaoka, S | 2 |
| Yasuda, T | 2 |
| Nakano, H | 2 |
| Ohigashi, H | 2 |
| Hiratsuka, M | 2 |
| Sasaki, Y | 2 |
| Kabuto, T | 2 |
| Ishikawa, O | 2 |
| Murata, K | 1 |
| Tsugawa, T | 1 |
| Furukawa, H | 1 |
| Shimazoe, T | 1 |
| Funakoshi, A | 2 |
| Kono, A | 2 |
| Harrison, JD | 1 |
| Jones, JA | 1 |
| Morris, DL | 2 |
| Charnley, RM | 1 |
| Ballantyne, KC | 1 |
| Jones, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 1 Study to Test Safety and Dose of Proglumide as an Anti-fibrotic Agent in Non-alcoholic Steatohepatitis (NASH)[NCT04152473] | Phase 1 | 18 participants (Actual) | Interventional | 2019-12-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for proglumide and Liver Neoplasms
| Article | Year |
|---|---|
[Adjuvant chemo-endocrine chemotherapy with gastrin antagonist after resection of liver metastasis in colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 1994 |
The effect of the gastrin receptor antagonist proglumide on survival in gastric carcinoma.
Topics: Aged; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pr | 1990 |
A pilot randomized control trial of proglumide (a gastrin receptor antagonist) in advanced colorectal cancer.
Topics: Adenocarcinoma; Carcinoembryonic Antigen; Colorectal Neoplasms; Humans; Liver Neoplasms; Neoplasm Re | 1990 |
7 other studies available for proglumide and Liver Neoplasms
| Article | Year |
|---|---|
Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cholecystokinin; Fibrosis; Immune Checkpoint Inhibitors; Liver N | 2023 |
Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemokines, CC; Cholecystokinin; Diet, High-Fa | 2021 |
A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Choline Deficiency; Disease Models, Animal; Ep | 2020 |
Colorectal carcinoma: prognostic significance of gastrin.
Topics: Colorectal Neoplasms; Gastrins; Humans; Indoles; Liver Neoplasms; Predictive Value of Tests; Proglum | 1995 |
[Adjuvant intra-arterial chemotherapy with gastrin receptor antagonist after hepatic resection in colorectal cancer metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Doxoru | 1998 |
[Effects of UFT and loxiglumide (CR1505) on liver metastasis of human pancreatic cancer cell line, KP-1 N in nude mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cholecystokinin; Humans; Liv | 1992 |
Growth inhibition of human pancreatic cancer cells by cholecystokinin receptor antagonist in tissue culture and in nude mice.
Topics: Adenocarcinoma; Animals; Ceruletide; Cholecystokinin; Humans; In Vitro Techniques; Liver Neoplasms; | 1992 |